Mara Finkelstein
Biographic Data
| ID | 10876369 |
|---|---|
| NAME | Mara Finkelstein |
| GIVEN NAMES | Mara |
| FAMILY NAME | Finkelstein |
| SIGNATURE | FINKELSTEIN M |
| AFFILIATIONS | Webb Institute |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 6 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1996 |
| LATEST PUBLICATION YEAR | 1996 |
| H-INDEX | 2 |
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The accepted sine qua non for estimating the difference in efficacy between a new and a standard treatment is a randomized controlled clinical trial. Yet in some situations it is either practically or ethically impossible to conduct such a trial. For example, patients who are desperately ill may decline to participate when they learn they may not receive the new treatment, especially when that treatment is readily available outside th…
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The preceding article proposed an assured treatment design that would address certain difficulties in recruiting persons who are at greater risk into randomized clinical trials. The purpose of this article is to illustrate the statistical validity of the design in a practical setting. METHODS: Three actual randomized clinical trials were considered as case studies; in each, the data that would have been obtained under assured allocati…
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The accepted sine qua non for estimating the difference in efficacy between a new and a standard treatment is a randomized controlled clinical trial. Yet in some situations it is either practically or ethically impossible to conduct such a trial. For example, patients who are desperately ill may decline to participate when they learn they may not receive the new treatment, especially when that treatment is readily available outside th…
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The preceding article proposed an assured treatment design that would address certain difficulties in recruiting persons who are at greater risk into randomized clinical trials. The purpose of this article is to illustrate the statistical validity of the design in a practical setting. METHODS: Three actual randomized clinical trials were considered as case studies; in each, the data that would have been obtained under assured allocati…
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The accepted sine qua non for estimating the difference in efficacy between a new and a standard treatment is a randomized controlled clinical trial. Yet in some situations it is either practically or ethically impossible to conduct such a trial. For example, patients who are desperately ill may decline to participate when they learn they may not receive the new treatment, especially when that treatment is readily available outside th…
Clinical and prophylactic trials with assured new treatment for those at greater risk
OBJECTIVES: The preceding article proposed an assured treatment design that would address certain difficulties in recruiting persons who are at greater risk into randomized clinical trials. The purpose of this article is to illustrate the statistical validity of the design in a practical setting. METHODS: Three actual randomized clinical trials were considered as case studies; in each, the data that would have been obtained under assured allocati…
Advanced Causal Inference Techniques (2 works) · Clinical trial (2 works) · Internal Medicine (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Statistical Methods in Clinical Trials (2 works) · Actuarial science (1 works) · Alternative medicine (1 works) · Economics (1 works) · Food and drug administration (1 works)